StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report published on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright restated a neutral rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.
Get Our Latest Stock Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million during the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
See Also
- Five stocks we like better than TRACON Pharmaceuticals
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How to Use Stock Screeners to Find Stocks
- AMD Gains Momentum With AI: Can It Beat Expectations?
- What to Know About Investing in Penny Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.